Highest-materiality recent filing
David Johnson and Jan Skvarka elected as Class III directors with 20.7M and 23.5M votes for, respectively.
Zentalis appoints Shannon Campbell as Class I director, expanding board to 7 members
Board increased from 6 to 7 directors; Campbell appointed as Class I director effective May 22, 2026.
Zentalis reports 39% ORR, 7.3-month median PFS for azenosertib+paclitaxel in PROC at ASCO
Phase 1b MUIR trial: all-comer PROC (n=46), ORR 39.1%, CBR 58.7%, median DOR 5.6 mo, median PFS 7.3 mo.
Zentalis Q1 2026 cash $211.8M; selects pivotal azenosertib dose; DENALI readout by year-end
Cash, cash equivalents and marketable securities $211.8M as of March 31, 2026; provides runway into late 2027.
Zentalis first patient dosed in Phase 3 ASPENOVA trial for azenosertib in Cyclin E1+ PROC
Phase 3 ASPENOVA compares azenosertib 400mg QD 5:2 to standard-of-care chemo in ~420 Cyclin E1+ platinum-resistant ovarian cancer patients.
Zentalis presents preclinical azenosertib data in TNBC; real-world ovarian cancer outcomes shown
Azenosertib + enfortumab vedotin induced 87.5% complete responses in ADC-resistant TNBC PDX model; 5 of 8 mice had no progression after treatment stop.
Pre-specified interim analysis from DENALI Part 2a showed clearly differentiated response rate at 400mg QD 5:2 over 300mg QD 5:2 and comparable safety profiles.
Zentalis reports FY2025 results; cash $245.9M, DENALI Part 2 topline due year-end 2026
Cash, equivalents and marketable securities $245.9M as of Dec 31, 2025; projected runway into late 2027.
Zentalis updates azenosertib program; DENALI Part 2 topline readout expected by year-end 2026
Completed enrollment in DENALI Part 2a, supporting registration-intended development of azenosertib.
Zentalis repurchases 7.5M shares from Matrix at $1.33 each; director resigns
Repurchased 7,500,000 shares from Matrix Capital Master Fund at $1.33/share, a 5% discount to the Dec 12 close of $1.40.
Zentalis Q3 cash $280.7M, cuts R&D spend 37% YoY; DENALI trial on track for data by YE2026
Cash and marketable securities $280.7M as of Sep 30, 2025; runway into late 2027.
Zentalis appoints James B. Bucher as Chief Legal Officer; Andrea Paul resigns to join law firm
Andrea Paul resigns as Chief Legal Officer and Corporate Secretary effective Sept 18, 2025.
Zentalis reports Q2 2025 cash of $303.4M; DENALI Phase 2 on track for topline by end 2026
Cash, cash equivalents and marketable securities $303.4M as of June 30, 2025; runway extended into late 2027.
Zentalis shareholders elect three directors, approve auditor and say-on-pay at annual meeting
Scott Myers (43.0M for), Karan Takhar (30.7M for), and Luke Walker (36.6M for) elected as Class II directors.
ORR of 35.3% (12/34 confirmed responses) in BRAF inhibitor-naïve patients; median DoR 6.0 months (95% CI 4.4-NE).
Zentalis to present at three investor conferences in May-June 2025
H.C. Wainwright BioConnect Conference – May 20, 2025, at 11:30 a.m. ET in New York, NY.
Zentalis Q1 2025 cash $332.5M; first patient dosed in DENALI Part 2 azenosertib trial
Cash $332.5M (incl. $12.2M Immunome stock) at March 31, 2025; runway into late 2027.
Azenosertib shows RB1 loss sensitivity in SCLC/TNBC; cfDNA MR predicts HGSOC response
Preclinical: RB1 loss sensitizes TP53-mutant SCLC/TNBC cells; in vivo TGI 90% in RB1-mutant vs 49% in WT xenografts (Ex-99.1).
Zentalis FY2024 cash $371.1M; azenosertib 34.9% ORR in PROC; cash runway to late 2027
Cash $371.1M; projected runway to late 2027. FY2024 op expenses $258.6M, down from $299.5M.
Azenosertib demonstrated ORR of 34.9% (15/43) in response-evaluable Cyclin E1+ PROC patients; mDOR 6.3 months (95% CI: 2.7–NE) as of Jan 13, 2025 cutoff.
DENALI Part 1b in Cyclin E1+ PROC achieved 34.9% ORR (response-evaluable n=43) and ~5.5 months median DOR; ITT ORR 31.3%.
Zentalis restructures with 40% workforce cut, focuses WEE1 inhibitor, cash to late 2027
Approves workforce reduction of approx. 40%; substantially complete by Q2 2025.
Zentalis appoints Scott Myers to Compensation Committee; annual retainer $7,500
Scott Myers appointed to Compensation Committee effective December 17, 2024.
Julie Eastland appointed CEO, President and Director effective Nov 13, 2024; succeeds Kimberly Blackwell who resigned as CEO but remains strategic advisor.
FDA lifts partial clinical hold on Zentalis' azenosertib studies; enrollment to resume
FDA cleared resumption of enrollment in all ongoing azenosertib studies with no changes to the clinical development plan.
Zentalis Q2 cash $426.4M; FDA partial hold on azenosertib; CMO resigns
Cash, equivalents and marketable securities $426.4M as of June 30; R&D expense $48.4M (Q2 2024); cash runway into mid-2026.
Zentalis shareholders elect Blackwell and Kariuki as directors; say-on-pay passes with 59% support
Kimberly Blackwell received 48,055,584 votes for (78.9%) and Enoch Kariuki 45,008,378 for (73.9%) to Class I director seats.
Zentalis files June 2024 corporate presentation; specific content not extractable from filing
Presentation furnished for use at investor conferences and meetings.
Zentalis appoints Luke Walker, M.D. to board, expanding to 7 directors
Board increased from 6 to 7 members; Dr. Walker appointed as Class II director effective May 24, 2024.
Zentalis Q1 cash $489M; multiple azenosertib data readouts H2 2024–2025
Cash, equivalents & marketable securities $489.0M (incl $56.7M Immunome stock); projected runway to mid-2026.
CFO Melissa Epperly resigns; President Cam Gallagher named interim CFO
Melissa Epperly resigned as CFO, treasurer, principal financial and accounting officer effective April 5, 2024.
Zentalis presents corporate deck at conferences; no new financial or clinical updates disclosed
Spokespersons to present the April 2024 corporate presentation at investor meetings and conferences.
Zentalis reports FY2023 cash $483M, azenosertib ORR 37%, appoints CMO/CBO
Cash, equivalents and securities $482.9M at Dec 31, 2023; runway into 2026; plus $35M upfront from Immunome in Jan 2024.
Zentalis adopts amended bylaws with universal proxy rule compliance
Board approved Amended and Restated Bylaws effective February 12, 2024.
Diana Hausman appointed CMO effective Jan 19, 2024; succeeds Carrie Brownstein who stepped down for personal reasons.
Zentalis licenses ROR1 ADC ZPC-21 to Immunome for $35M upfront, up to $275M milestones
Exclusive worldwide license of preclinical ROR1 ADC ZPC-21 and proprietary ADC platform to Immunome.
Zentalis Q3: azenosertib 37% ORR, $517M cash, NDA on track for 2026
Azenosertib monotherapy achieved 37% ORR and 6.5-month mPFS in heavily pretreated ovarian/uterine serous carcinoma.
Zentalis Pharmaceuticals COO Iris Roth departs effective Oct 10, 2023
Dr. Iris Roth ceases as COO at 11:59 p.m. ET on Oct 10, 2023.
Zentalis Pharmaceuticals furnishes corporate presentation; no specific new data disclosed in excerpt
Presentation dated September 2023 will be used in investor meetings and conferences.
Zentalis Q2 cash $553M; azenosertib ORR 36.8% with RP2D set
Cash, equivalents and marketable securities $553.0M as of June 30, 2023; runway into 2026.
No earnings, guidance, or clinical data included in the 8-K filing.
Zentalis shareholders reject advisory say-on-pay vote at 2023 annual meeting
Advisory vote on executive compensation failed: 18.7M for, 34.3M against, 14K abstain.
Zentalis prices public offering of 11M shares at $22.66, raising ~$235.5M
Sale of 11,032,656 common shares at $22.66 per share; net proceeds estimated at $235.5M.
Zentalis regains global rights to azenosertib, ZN-d5, ZN-c5 from Zentera
Terminated collaboration with Zentera Therapeutics; now holds worldwide development/commercialization rights to three drug candidates.
Zentalis announces azenosertib monotherapy RP2D with 36.8% ORR in ovarian/USC
RP2D set at 400 mg QD on 5:2 schedule; steady-state exposure more than doubled vs continuous dosing.
Zentalis presents ASCO data: azenosertib+chemo response linked to Cyclin E1
Azenosertib + chemo (paclitaxel, carboplatin, gemcitabine, PLD) shows ORR of 34% across 94 evaluable patients.
Azenosertib + paclitaxel achieved 50% ORR (7.4 months mPFS) in platinum-resistant ovarian cancer.
Zentalis reports $392M cash; on track for azenosertib monotherapy dose, ASCO data
Cash, cash equivalents and marketable securities of $392M as of March 31, 2023; runway into Q2 2025.
Positive clinical data from Phase 1b trial of azenosertib + chemo in platinum-resistant ovarian cancer to be presented at ASCO June 5, 2023.
Preclinical data show azenosertib kills Cyclin E1-high tumor cells in vitro and inhibits patient-derived in vivo models.
Effective May 22, 2026, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) increased its size from six to seven directors and appointed Shannon Campbell, as a Class I director.
On November 12, 2024, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) appointed Julie Eastland as Chief Executive Officer, President and a Class I director of the Company with an initial term scheduled to expire at the Company’s 2027 Annual Meeting of Stockholders, in each case effective November 13, 2024 (the “Transition Date”).
Also on November 12, 2024, Kimberly Blackwell, M.D., resigned as Chief Executive Officer, a member of the Board and from all other positions held with the Company and its affiliates, effective on the Transition Date.
On and effective May 24, 2024, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) increased its size from six to seven directors and appointed Luke Walker, M.D., as a Class II director.
the Company’s Vice President, Finance, Vincent Vultaggio, as interim principal accounting officer
On January 25, 2024, Zentalis Pharmaceuticals, Inc. (the “Company” or “Zentalis”) announced that Diana Hausman, M.D., a member of the Company’s Board of Directors (the “Board”), had succeeded Carrie Brownstein, M.D. as Chief Medical Officer of the Company, effective January 19, 2024
Dr. Brownstein stepped down for personal reasons.
Dr. Hausman resigned from the Board, the Audit Committee of the Board (“Audit Committee”), and the Nominating and Corporate Governance Committee of the Board.
On Friday, October 6, 2023, Zentalis Pharmaceuticals, Inc. (the “Company”) announced that Iris Roth, Ph.D., Chief Operating Officer of the Company, will depart from the Company and cease serving as Chief Operating Officer of the Company, effective as of 11:59 p.m. Eastern Time on Tuesday, October 10, 2023.
On February 13, 2023, Zentalis Pharmaceuticals, Inc. (the “Company”) publicly announced the appointment of Iris Roth, Ph.D. as Chief Operating Officer of the Company, effective as of February 13, 2023
On and effective September 26, 2022, Kevin Bunker was promoted to Chief Scientific Officer of Zentalis Pharmaceuticals, Inc. (the “Company”) and, as a result of his promotion, stepped down as Chief Operating Officer of the Company.
On and effective September 9, 2022, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) appointed Jan Skvarka, Ph.D., M.B.A., as a Class III director.
Max materiality 0.85 · Median 0.65 · Most common event other_material